Cascade Financial Partners’s Protalix BioTherapeutics PLX Stock Holding History

Cascade Financial Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26K	Hold	12,000	–	–	﹤0.01%	262
2025 Q4	$21.6K	Sell	12,000 -5,000	-29%	-$10.2K	﹤0.01%	271
2025 Q3	$37.7K	Hold	17,000	–	–	﹤0.01%	261
2025 Q2	$25.2K	Buy	+17,000	New	+$34.8K	﹤0.01%	259
2024 Q3	–	Sell	-11,100	Closed	-$13K	–	242
2024 Q2	$13K	Buy	+11,100	New	+$13.1K	﹤0.01%	233

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Cascade Financial Partners's PLX Position: Q1 2026 in Review

Cascade Financial Partners held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 12,000 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #262.

Cascade Financial Partners first reported a position in PLX in Q2 2024 and has held it in 5 quarters since. The position peaked at $37.7K in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Cascade Financial Partners held 12,000 shares of Protalix BioTherapeutics worth $26K as of Q1 2026.
Cascade Financial Partners left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Cascade Financial Partners's portfolio in Q1 2026, its #262 holding.
Cascade Financial Partners first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 5 quarters since.
Cascade Financial Partners's Protalix BioTherapeutics position peaked at $37.7K in Q3 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Cascade Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.